Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Issues Letter to Stockholders

180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, on Monday released a letter to stockholders from its CEO Dr. James Woody. The letter addresses the closing of the merger with KBLM Merger Corp IV, which resulted in 180 Life Sciences now operating as a stand-alone publicly traded company with its common stock listed on the Nasdaq Capital Market under the symbol “ATNF.” In the update, Dr. Woody shares a little about himself and the world class team of scientists, physicians, and executives that now comprise the 180 Life Sciences management team and board of directors. He also discusses the company’s drug pipeline and plans moving forward, including what lies ahead and anticipated critical milestones. “I started my career in biotech as the Chief Scientific Officer and Senior Vice President of Research and Development at Centocor, where I led the team responsible for developing Remicade, the first of the TNF (tumor necrosis factor) inhibitor biologics,” Dr. Woody states in the letter. “This was in collaboration with Prof. Sir Marc Feldmann, one of the founders of 180 Life Sciences and the current Co-Chairman of the Board of Directors. Marc and I go back a long way, to the late 70s. Remicade was a breakthrough product, it was the first anti-TNF to show dramatic efficacy and triggered the ‘antibody revolution.’ According to a report in FiercePharma, Remicade sales topped $7 billion USD in 2016 and were $5 billion in 2019.”

To view the full press release, visit https://ibn.fm/UqGqS

About 180 Life Sciences Corp.

180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The company is driving groundbreaking study into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The company’s primary platform is a novel program to treat fibrosis using anti-TNF (tumor necrosis factor), with its lead program in phase 2b/3 clinical trials. For more information about the company, visit www.180LifeSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at https://ibn.fm/ATNF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

This entry was posted in 180 Life Sciences Corp., MissionIRNewsBreaks. Bookmark the permalink.

Comments are closed.